Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib in First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
NCT04704219Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Merck & Co. Primary endpoint: Objective Response Rate at 47 months. Started Feb 2021; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT04704219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704219.